2.93

1.68% -0.05

Pre-market: 2.94 0.010 +0.34%

Adverum Biotechnologies Inc (ADVM)

Overview News Price History Option Chain Financials Discussions Forecast

Adverum Biotechnologies Inc stock is traded at $2.93, with a volume of 307.56K. It is down -1.68% in the last 24 hours and down -38.05% over the past month. Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.

Previous Close:

$2.98

Open:

$3.01

24h Volume:

307.56K

Relative Volume:

1.79

Market Cap:

$71.65M

Revenue:

Net Income/Loss:

$-94.11M

P/E Ratio:

-0.4875

EPS:

-6.01

Net Cash Flow:

$-86.06M

1W Performance:

-12.01%

1M Performance:

-38.05%

6M Performance:

-63.74%

1Y Performance:

-74.19%

1-Day Range:

$2.745

$3.01

1-Week Range:

$2.745

$3.71

52-Week Range:

$2.745

$11.87

Adverum Biotechnologies Inc Stock (ADVM) Company Profile

Name

Adverum Biotechnologies Inc

Sector

Healthcare (1151)

Industry

Biotechnology (660)

Phone

(650) 649-1004

Address

100 CARDINAL WAY, REDWOOD CITY, CA

Employee

155

Twitter

@adverumbio

Next Earnings Date

2024-11-07

Latest SEC Filings

ADVM's Discussions on Twitter

Compare ADVM with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ADVM Adverum Biotechnologies Inc	2.93	71.65M	0	-94.11M	-86.06M	-6.01
VRTX Vertex Pharmaceuticals Inc	489.10	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	563.16	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	596.20	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	234.56	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	230.98	26.16B	3.81B	-644.79M	-669.77M	-6.24

Adverum Biotechnologies Inc Stock (ADVM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-25-24	Initiated	Oppenheimer	Outperform
Apr-30-24	Initiated	H.C. Wainwright	Buy
Jul-07-22	Upgrade	Truist	Hold → Buy
Jul-23-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral
May-03-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Apr-29-21	Downgrade	Chardan Capital Markets	Buy → Neutral
Apr-29-21	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Apr-29-21	Downgrade	Truist	Buy → Hold
Dec-16-20	Initiated	UBS	Neutral
Nov-12-20	Upgrade	Raymond James	Underperform → Mkt Perform
Jun-26-20	Downgrade	Raymond James	Mkt Perform → Underperform
May-13-20	Initiated	RBC Capital Mkts	Outperform
May-05-20	Upgrade	SunTrust	Hold → Buy
Apr-28-20	Initiated	Goldman	Buy
Mar-16-20	Initiated	SVB Leerink	Outperform
Feb-10-20	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Feb-10-20	Upgrade	Chardan Capital Markets	Neutral → Buy
Oct-15-19	Reiterated	Chardan Capital Markets	Neutral
Sep-13-19	Reiterated	Chardan Capital Markets	Neutral
Jun-14-19	Resumed	Raymond James	Mkt Perform
Nov-02-18	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-02-18	Downgrade	SunTrust	Buy → Hold
Sep-21-18	Initiated	Cantor Fitzgerald	Overweight
Aug-30-18	Initiated	SunTrust	Buy
Feb-15-18	Resumed	Piper Jaffray	Overweight
Oct-12-17	Initiated	Raymond James	Outperform

View All

Adverum Biotechnologies Inc Stock (ADVM) Latest News

06:49 AM

Truist Removes $40 Price Target on Adverum Biotechnologies, Cites Share Volatility, Keeps Buy Rating - marketscreener.com

06:49 AM

Apr 20, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Adverum Biotechnologies, Inc. (ADVM) Investors to Inquire about Securities Investigation - markets.businessinsider.com

Apr 20, 2025

Apr 18, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Adverum Biotechnologies, Inc. (ADVM) And Encourages Investors to Reach Out - markets.businessinsider.com

Apr 18, 2025

Apr 17, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Adverum Biotechnologies, Inc. (ADVM) And Encourages Stockholders to Reach Out - markets.businessinsider.com

Apr 17, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - GlobeNewswire Inc.

Apr 17, 2025

Intuit To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga

Apr 17, 2025

Apr 16, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Adverum Biotechnologies, Inc. (ADVM) And Encourages Stockholders to Connect - markets.businessinsider.com

Apr 16, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 16, 2025

RBC Cuts Price Target on Adverum Biotechnologies to $5 From $10, Keeps Sector Perform, Speculative Risk - marketscreener.com

Apr 16, 2025

Apr 15, 2025

Adverum Biotechnologies Reports 2024 Financial Results and Pipeline Progress - TipRanks

Apr 15, 2025

Adverum Biotechnologies: Q4 Earnings Snapshot - CT Insider

Apr 15, 2025